Logotype for Compass Therapeutics Inc

Compass Therapeutics (CMPX) investor relations material

Compass Therapeutics Morgan Stanley 23rd Annual Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Compass Therapeutics Inc
Morgan Stanley 23rd Annual Global Healthcare Conference summary9 Sep, 2025

Pipeline progress and clinical updates

  • Lead bispecific antibody Tavecimab achieved primary endpoint in a randomized trial for biliary tract cancer, showing a 17.1% response rate versus 5.3% for control, with statistical significance.

  • Fewer deaths than projected in the Tavecimab study suggest a potential treatment effect, with updated guidance for secondary endpoint data in Q1 2026.

  • Investigator-led study at MD Anderson is evaluating Tavecimab in first-line therapy, potentially expanding its use and commercial opportunity.

  • Phase II basket study for Tavecimab in DLL4-positive cancers is planned for the first half of next year, targeting multiple tumor types.

  • Fast-track status and potential for a U.S. license application in 2026, with possible approval in early 2027.

Innovation in bispecific antibodies

  • H371, a PD1-PDL1 bispecific, demonstrated deep responses in refractory non-small cell lung and triple-negative breast cancer patients, with no dose-limiting toxicities in early phase I.

  • H371’s novel mechanism converts PD1-positive T cells to functional PD1-negative T cells, representing a next-generation checkpoint inhibitor.

  • Expansion cohorts for H371 in lung and breast cancer will begin in Q4, with full dose escalation data expected at a medical meeting later this year.

  • 10726, a PD1-VEGF8 bispecific, showed superior preclinical efficacy to Ivernizumab and is set for IND filing in Q4, with clinical entry in 2026.

Manufacturing and operational readiness

  • Developed significant bispecific manufacturing expertise, achieving commercial-ready yields of five grams per liter for all three bispecifics.

  • BLA-ready manufacturing runs for Tavecimab have been initiated to support potential regulatory filings.

  • Manufacturing capability is seen as a key differentiator, surpassing yields of some leading monoclonal antibodies.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Compass Therapeutics earnings date

Logotype for Compass Therapeutics Inc
Q3 202511 Nov, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Compass Therapeutics earnings date

Logotype for Compass Therapeutics Inc
Q3 202511 Nov, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics primarily targeting oncology. The company’s research centers on the interaction between angiogenesis, the immune system, and tumor growth. Its pipeline includes novel therapeutic candidates designed to modulate key biological pathways to elicit an effective anti-tumor response. This includes strategies to influence the tumor microvasculature, activate immune cells, and overcome immunosuppressive mechanisms employed by tumors. The company is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage